The authors used data from a population-based, case-control study of breast cancer conducted among women residing in King County, Washington State, who were 50-64 years of age in 198&-1990, to examine the relation of oral contraceptive use to the risk of breast cancer. There were no clear differences between cases and controls with respect to the total duration of oral contraceptive use, time since last use, or age at first or last use. While a small increase in risk was noted in women who had first used oral contraceptives within 20 years of the interview reference date, within that period there was no trend in risk observed with decreasing amounts of time since the last use of these agents. Overall, this study supports the absence of any strong association between oral contraceptive use and breast cancer risk during middle age in the cohort of women who first used these drugs. Am J Epidemiol 1996; 144:161-4. breast neoplasms; contraceptives, oral
Oral contraceptives first became available in the United States in the 1960s, and the cohort of women who first used these drugs is now in middle age. Thus, for women in the age range during which breast cancer most frequently occurs, little information is yet available regarding the possible impact of oral contraceptive use on the risk of this disease. We used data from a population-based, case-control study of breast cancer conducted among women who were 50-64 years of age in [1988] [1989] [1990] to examine the relation of oral contraceptive use with the risk of breast cancer occurring in middle age.
MATERIALS AND METHODS
The study population and methods have been described previously (1) . Briefly, cases were identified through the Cancer Surveillance System, a populationbased cancer registry operating as part of the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Eligible cases included all white women residing in King County, Washington State, who were aged 50-64 years and were diagnosed with histologically confirmed first primary invasive or in situ carcinoma of the breast between January 1988 and June 1990. A total of 660 eligible cases were identified, of whom 537 (81.4 percent) were interviewed.
Controls were King County women identified through random digit telephone dialing (2, 3) and were selected to be similar in age to the cases. Complete household census information was obtained for 96 percent of the residences contacted via telephone screening. Based on that screening, we identified 747 eligible women and interviewed 545 (73.0 percent). Fifty-three women who reported a previous diagnosis of breast cancer or who were nonwhite were excluded, leaving 492 controls for analysis.
Controls were assigned a reference date (month and year) that approximated the distribution of diagnosis dates among the cases. Information was obtained during an in-person interview using a structured questionnaire that pertained to events before diagnosis (cases) or reference date (controls). The interview included questions on menstrual and reproductive histories, medical history, use of exogenous hormones (contraceptive and noncontraceptive), family history of breast cancer, body size, diet, alcohol consumption, smoking habits, and demographic characteristics. A calendar of life events (such as dates of marriages and pregnancies) and color pictures of oral contraceptive preparations were used to enhance recall. For each episode of oral contraceptive use, participants were asked to report the reason for use, the beginning and ending dates, the brand used, complications that may have occurred, and the reason for discontinuing use.
Based on the brand name reported, oral contraceptive use was classified by formulation (combination, sequential, or progestin only) and by estrogenic and progestational potencies. The method of Dickey (4) , as expanded by the American Medical Association Department of Drugs (5,6), was used for classifying oral contraceptive potency, as described previously (7) . We considered oral contraceptives as having "high" estrogenic potency if they were classified in the +3 or +4 estrogenic potency categories and as having "high" progestational potency if they were classified in the +3 or +4 progestational potency categories.
Logistic regression was used to estimate the odds ratio as a measure of the relative risk of breast cancer that was associated with various aspects of oral contraceptive use, while controlling for the confounding effects of other variables (8) . Characteristics examined as potentially confounding the associations of interest included age, age at menarche, age at first full-term pregnancy, number of full-term pregnancies, body mass index, family history of breast cancer, use of hormone replacement therapy, alcohol use, education, and menopausal status.
RESULTS
Cases and controls were similar with respect to age, age at menarche, use of menopausal hormone replacement therapy (of any type), history of benign breast disease, and menopausal status. Cases were somewhat more likely than controls to be nulliparous, to have had a later age at first full-term pregnancy, and to have ever consumed alcohol; also, cases had relatively greater body mass and were more likely to report a family history of breast cancer (table 1) .
A similar proportion of cases and controls had ever used oral contraceptives. Only a very small proportion of women reported oral contraceptive use before the first full-term pregnancy, and this proportion was similar among cases (2.2 percent) and controls (2.4 percent). There were no clear differences between cases and controls with respect to the total duration of oral contraceptive use, time since last use, or age at first or last use (table 2) . While a small increased risk was noted in women who had first used oral contraceptives within 20 years of the interview reference date, within that period there was no trend in risk observed with decreasing amounts of time since the last use of these agents. Also, no trend in risk was evident regarding the duration of use among women who had first used oral contraceptives within 20 years of the reference date.
We noted no important differences in the relation of breast cancer risk with the duration of oral contraceptive use, time since first or last use, or age at first or last use among women of different 5-year age groups (results not shown). Also, no clear differences in the use of oral contraceptives between cases and controls were apparent when other subgroups of women were compared, including women with versus without a family history of breast cancer, parous versus nulliparous women, and ever versus never users of menopausal hormone replacement therapy. Among women who had used oral contraceptives, 40.7 percent of cases and 46.5 percent of controls failed to recall sufficient information to classify any of * Adjusted for age. t Also adjusted for age at menarche, age at first term pregnancy, body mass index, and family history of breast cancer.
t Numbers in parentheses, 95% confidence interval. § Missing data for two cases and one control.
the oral contraceptives used by formulation and, for an additional 3.2 percent of cases and 5.3 percent of controls, the formulation could be identified for some, but not all, episodes of use. Among women for whom the formulation used was known, the vast majority had used only combination oral contraceptives (93.9 percent of cases and 93.3 percent of controls). Similarly, estrogenic and progestational potencies could not be assigned for some or all episodes of oral contraceptive use for relatively large proportions of cases and controls, and this proportion was greater among controls (54.0 percent of oral contraceptive users) than cases (46.2 percent). Among women for whom potency information could be calculated for all episodes of oral contraceptive use (136 cases and 104 controls), high potency estrogen use was reported by 19.1 percent of cases and 26.0 percent of controls, while the use of high progestational potency oral contraceptives was reported by 15.4 percent of both cases and controls.
DISCUSSION
It is possible that differences in characteristics of women who did or did not choose to participate may influence our results, as could errors in recall of the timing of oral contraceptive use. Our ability to assess Am J Epidemiol Vol. 144, No. 2, 1996 differences in the effects of various oral contraceptive formulations, as well as differences by estrogenic or progestational potencies of the oral contraceptives used, was limited by the large proportion of women who could not recall the brand and/or strength of the preparation(s) used.
While the women in this study were of the age range of US women who first used oral contraceptives, few women in the study used these drugs at a very early age or before the first full-term pregnancy. We are thus unable to assess the effect of oral contraceptive use at periods that have been associated, in some studies of younger women, with elevations in breast cancer risk (7, 9) .
The use of oral contraceptives relatively late in reproductive life (after age 40) was fairly common in this study population, and such use was not associated with any clear alteration in the risk of breast cancer. The effect of using oral contraceptives in late reproductive life has been investigated in only a few studies (see refs. 9 and 10 for review), and not all of these have presented risk estimates for women aged 50 or more years. Two studies found no increase in the risk associated with the duration of oral contraceptive use after the age of 40 (11) or 45 (12) in either pre-or postmenopausal women. In the latter study, while oral contraceptive use within the past year was associated with an increased risk in women less than 50 years of age, no increase in risk was noted among recent or other users aged 50 years or older. In the study of Wingo et al. (13) , women aged 45-54 years who had ever used oral contraceptives had a slightly reduced risk of breast cancer (relative risk = 0.9, 95 percent confidence interval 0.8-1.0), and the risk decreased with increasing time since first and last use.
We noted a small increased risk of breast cancer only among women who had begun using oral contraceptives within the past 20 years. Our result is opposite to what would be expected if (as has been hypothesized (14)) a long induction period after first using oral contraceptives was required prior to these drugs' influencing the risk of breast cancer. Within this group, there was no trend in risk by duration of use; also, similar proportions of these cases and controls had initiated oral contraceptive use as birth control or for some other purpose (e.g., regulation of menstrual cycles). Overall, this study supports the absence of any strong association between oral contraceptive use and breast cancer risk during middle age in the cohort of women who first used these drugs.
